home / news & insights /
On 28 April 2023 Damiën Berkhout was a panelist at the Global Class Actions and Mass Torts Conference. He spoke on a panel dealing with “Assignments of claims – a favourable model in some European jurisdictions.”
Damiën discussed under what conditions the assignment model can be used to litigate mass tort claims, and commented that the model will continue to exist even now that the WAMCA and Directive 2020/1828 provide for opt-out class action opportunities in The Netherlands. He outlined the ways in which the assignment model can be a more effective way to resolve certain disputes, compared to the WAMCA- or mandate-model.
During the conference, Damiën had a lively conversation with the audience and his co-panelists, Anja Meier Hoffman (Hengeler Mueller – Dr. Anja Meier-Hoffmann), Giorgio Efferni (Giorgio Afferni – Delex Law Firm) and the chair of the panel, professor Geraint Howells (Geraint Howells (europeanlawinstitute.eu).
The Global Class Actions and Mass Torts Conference is a yearly, leading class action conference with class action practitioners from all over the world. For more about the conference, visit the website Perfect Law LTD – Perfect Law
If you want to learn more about assignments of claims, do not hesitate to contact the experts at Lindenbaum.
25 September 2024 - Insights
Lindenbaum is moving to its new Amsterdam offices at Concertgebouwplein 13. We look forward to meeting you there.
Read more5 September 2024 - Insights
Lindenbaum's managing partner Damiën Berkhout provided legal and governance advice to the management board of Beequip in the context of the transaction between NIBC and Apollo.
Read more5 September 2024 - News
The Amsterdam District Court ruled that the representative organization Stichting Farma Ter Verantwoording is admissible in its collective action against pharmaceutical giant AbbVie. The case now moves on to the merits phase, in which the court will assess whether Abbvie abused its dominant position and violated human rights by charging excessive prices for its Humira medicine.
Read more